PhoenixBio Co., Ltd. (6190.T)
Tokyo · JPY · Healthcare · Biotechnology
¥299 (-4.17%) as of
Key statistics
- Market cap
- 1.22B
- P/E (TTM)
- 81.03
- EPS (TTM)
- 3.69
- Dividend yield
- 0.00%
- 52-week range
- 289.00 – 637.00
- Beta
- 0.37
- Revenue (TTM)
- 1.42B
- Profit margin
- 1.05%
- Volume
- 10.00k
About PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract testing services for pharmaceutical development in Japan, the United States, Europe, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver; and PXB-cells, a human hepatocyte for studies which require the use of primary human hepatocytes, such as drug metabolism, enzyme induction/inhibition, safety assessment, transporter evaluation, anti-HBV therapeutics efficacy testing, and other studies. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. PhoenixBio Co., Ltd. was incorporated in 2002 and is headquartered in Higashihiroshima, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Higashihiroshima, Japan
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.